Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Anklesaria P (2000) Gene therapy: A molecular approach to cancer treatment. Curr Opin Mol Ther 2, (4):426–432
Bergsland E, Mani S, Kirn D, Fell S, Heise C, Maack C, Venook A and Warren R (1998) Intratumoral injection of ONYX-015 for gastrointestinal tumors metastatic to the liver: A phase I trial. Proc Am Soc Clin Oncol 17: 211a
Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A and McCormick F (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274: 373–376
Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova J-L, Bousso P, Le Deist F and Fischer A (2000) Gene therapy of human severe combined immunodeficiency (SCID)-XI disease. Science 288, (5466):669–672
Clayman GL, El-Naggar AK, Lippman SM, Henderson YC, Frederick M, Merritt JA, Zumstein LA, Timmons TM, Liu T-J, Ginsberg L, Roth JA, Hong WK, Bruso P and Goepfert H (1998) Adeovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 16, (6):2221–2232
Coffey MC, Strong JE, Forsyth PA and Lee PW (1998) Reovirus therapy of tumors with activated Ras pathway. Science 282: 1332–1334
Crystal R (1995) Transfer of genes to humans: early lessons and obstacles to success. Science 270: 404–410
Daniels GA and Galanis E (2001) Immunotherapy of renal cell carcinoma by intratumoral administration of an IL-2 cDNA/DMRIE/DOPE lipid complex. Curr Opin Mol Ther 3, (1):70–76
Galanis E, Hersh EM, Stopeck AT, Gonzalez R, Burch P, Spier C, Akporiaye ET, Rinehart JJ, Edmonson J, Sobol RE, Forscher C, Sondak VK, Lewis BD, Unger EC, O’Driscoll M, Selk L and Rubin J (1999) Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: Phase I/II experience. J Clin Oncol 17, (10):3313–3323
Georger B, Grill J, Opolon P, Terrier-Lacombe M, Morizet J, Aubert G, Kirn DH and Vassal G (2001) ONYX-015, an E1B-55kD deleted adenovirus, potentiates radiation therapy in human malignant glioma xenografts. Proc Am Soc Clin Oncol 20: 53a
Goodrum FD and Ornelles DA (1998) p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J Virol 72: 9479–9490
Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD and Kirn DH (1997) ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3: 639–645
Herman JR, Adler HL, Aguilar-Cordova E, Rojas-Martinez A, Woo S, Timme TL, Wheeler TM, Thompson TC and Scardino PT (1999) In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial. Hum Gene Ther 10: 1239–1249
Hersch EM and Stopeck AT (1997) Advances in the biological therapy and gene therapy of malignant disease. Clin Cancer Res 12, Pt2:2623–2629
Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, Gore M, Ironside J, MacDougall RH, Heise C, Randlev B, Gillenwater AM, Bruso P, Kaye SB, Hong WK and Kirn DH (2000) A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6, (8):879–885
Klatzmann D, Valery CA, Bensimon G, Marro B, Boyer O, Mokhtari K, Diquet B, Salzmann JL and Philipporn J (1998) A phase I/II study of herpes simplex virus type I thymidine kinase ‘suicide’ gene therapy for recurrent glioblastoma. Hum Gene Ther 9: 2595–2604
Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F and Martuza RL (2000) Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial. Gene Ther 7: 867–874
Marshall E (1999) Clinical trials: Gene therapy death prompts review of adenovirus vector. Science 286: 2244–2245
Mastrangelo MJ, Maguire HC, Eisenlohr LC, Laughlin CE, Monken CE, McCue PA, Kovatich AJ and Lattime EC (1999) Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 6: 409–422
Molnar-Kimber KL, Sterman DH, Chang M, Kang EH, ElBash M, Lanuti M, Elshami A, Gelfand K, Wilson JM, Kaiser LR and Albelda SM (1998) Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum Gene Ther 9, (14):2121–2133
Mulvihill SJ, Warren R, Venook A, Adler A, Randlev B, Heise C and Kirn D (2001) Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: A phase I trial. Gene Ther 8, (4):308–315
Nemunaitis J, Swisher SG, Timmons T, Connors D, Mack M, Doerksen L, Weill D, Wait J, Lawrence DD, Kemp BL, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB, Richli WR, Shin DM, Walsh GL, Merritt J and Roth J (2000) Adenovirus mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 18: 609–622
Nielsen LL, Lipari P, Dell J, Gurnani M and Hajian G (1998) Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Clin Cancer Res 4: 835–846
Pecora AL, Rizvi N, Cohen GI, Meropol NJ, Sterman D, Marshall J and Lorence RM (2001) An intravenous phase I trial of a replication-competent virus, PV701, in the treatment of patients with advanced solid cancers. Proc Am Soc Clin Oncol 20: 253a
Rainov NG (2000) A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 11: 2389–2401
Ram Z, Culver KW, Oshiro EM, Viola JJ, DeVroom HL, Otto E, Long Z, Chiang Y, McGarrity GJ, Muul LM, Blaese RM and Oldfield EH (1997) Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nature Med 3: 1354–1361
Ready T (2001) RAC tries to regain foothold. Nature Med 7, (9):983
Reid T, Galanis E, Abbruzzese J, Sze D, Romel L, Hatfield M, Rubin J and Kirn D (2000) Hepatic artery infusion of Onyx-015, a selectively-replicating adenovirus, in combination with 5-FU/leucovorin for gastrointestinal carcinoma metastatic to the liver: a phase I/II trial. Proc Am Soc Clin Oncol 19: 246a
Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW and Henderson DR (1997) Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 57: 2559–2563
Roth JA and Cristiano RJ (1997) Gene therapy for cancer: What have we done and where are we going?. J Natl Cancer Inst 89: 21–39
Roth JA, Nguyen D and Lawrence DD (1996) Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 2: 985–991
Rothman T, Hengstermann A, Whitaker NJ, Scheffner M and zur Hausen H (1998) Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol 72: 9470–9478
Rubin J, Galanis E, Pitot HC, Richardson RL, Burch PA, Charboneau JW, Reading CC, Lewis BD, Stahl S, Akporiaye ET and Harris DT (1997) Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7B7. Gene Ther 4: 419–425
Russell SJ (1994) Replicating vectors for gene therapy of cancer: Risks, limitations and prospects. Eur J Cancer 30, (A):1165–1171
Schuler M, Herrmann R, DeGreve JL, Stewart AK, Gatzemeier U, Stewart DJ, Laufman L, Gralla R, Kuball J, Buhl R, Heussel CP, Kommoss F, Perruchoud AP, Shepherd FA, Fritz MA, Horowitz JA, Huber C and Rochlitz, (2001) Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. J Clin Oncol 19, (6):1750–1758
Simons JW, Jaffee EM, Weber CE, Levitsky HI, Nelson WG, Carducci MA, Lazenby AJ, Cohen LK, Finn CC, Clift SM, Hauda KM, Beck LA, Leiferman KM, Owens AH Jr., Piantadosi S, Dranoff G, Mulligan RC, Pardoll DM and Marshall FF (1997) Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 57: 1537–1546
Simons JW, Mikhak B, Van Der Poel HG, DeMarzo A, Rodriguez R, Goemann MA, Nelson WG, Li S, Detorie N, Hamper UM, Ramakrishna N and DeWeese TL (2000) Molecular and clinical activity of CN706, a PSA-selective oncolytic AD5 vector in a phase I trial in locally recurrent prostate cancer following radiation therapy. Mol Ther 1, (5):S144–S145
Sterman DH, Treat J, Litzky LA, Amin KM, Coonrod L, Molnar-Kimber K, Recio A, Know L, Wilson JM, Albelda SM and Kaiser LR (1998) Adenoviruis-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 9: 1083–1092
Stopeck AT, Hersh EM, Akporiaye ET, Harris DT, Grogan T, Unger E, Warneke J, Schluter SF and Stahl S (1997) Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol 15: 341–349
Sweeney P and Pisters LL (2000) Ad5CMVp53 gene therapy for locally advanced prostate cancer – where do we stand?. World J Urol 18: 121–124
Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, Connors DG, El-Naggar AK, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Mack M, Merritt JA, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KMW, Putnam JB Jr., Richli WR, Savin M, Schrump DS, Shin DM, Shulkin A, Walsh GL, Wait J, Weill D and Waugh MKA (1999) Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 91: 763–771
Swisher SG, Roth JA, Komaki R, Hicks M, Ro J, Dreiling L, Yver AB, Stevens C, Putnam JB Jr., Smythe WR, Vaporciyan AA and Walsh GL (2000) A phase II trial of adenoviral mediated p53 gene transfer (RPR/INGN 201) in conjunction with radiation therapy in patients with localized non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 19: 461a
Tait DL, Obermiller PS, Redlin-Frazier S, Jensen RA, Welcsh P, Dann J, King M-C, Johnson DH and Holt JT (1997) A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer. Clin Cancer Res 3: 1959–1968
Vasey PA, Seiden M, O’Neill V, Campo S, Johnston S, Davis J, Kirn D, Kaye SB and Shulman LN (2000) Phase I trial of intraperitoneal Onyx-015 adenovirus in patients with recurrent ovarian cancer. Proc Am Soc Clin Oncol 19: 382a
Venook AP, Bergsland EK, Ring E, Nanoka-Wong S, Horowitz JA, Rybak ME and Warren RS (1998) Gene therapy of colorectal liver metastases using a recombinant adenovirus encoding WT p53 (SCH 58500) via hepatic artery infusion: a phase I study. Proc Am Soc Clin Oncol 1661, (17):431a
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Galanis, E., Russell, S. Cancer gene therapy clinical trials: lessons for the future. Br J Cancer 85, 1432–1436 (2001). https://doi.org/10.1054/bjoc.2001.2129
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.2129
Keywords
This article is cited by
-
Violacein, an indole-derived purple-colored natural pigment produced by Janthinobacterium lividum, inhibits the growth of head and neck carcinoma cell lines both in vitro and in vivo
Tumor Biology (2016)
-
Transferrin-Associated Lipoplexes as Gene Delivery Systems: Relevance of Mode of Preparation and Biophysical Properties
Journal of Membrane Biology (2008)
-
Oncolytic adenoviruses – selective retargeting to tumor cells
Oncogene (2005)